Anavex Life Sciences Corp (AVXL)

[Anshu2]

First, you really need to understand AA.

Second, you need to understand Sareptr’s failure better — in particular, NSAA endpoint.

Third — most importantly — LAW doesn’t say anything about “primary endpoint” or p<0.05 requirement. All it says is “substantial evidence”. Point being — FDA decides what is substantial evidence, which in almost all cases is TWO successful trials or ONE compelling and successful trial. Again — AA vs ffull approval is the same criteria — just the “endpoints” differ.